GSTP1 and breast cancer: Homozygotes with GSTP1 105Val allele were more frequent in the controls than in the BC patients (10.7 % vs. 7.8 %) and applied dominant model indicated that GSTP1 105Val allele carriers showed non-significantly decreased BC risk (adjusted OR 0.81, 95 % CI 0.57–1.14).